[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614476":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":52,"locations":63,"responsibleParty":84,"collaborators":86,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":10,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Netherton syndrome",null,"15 children, adolescents, and young adults with Netherton syndrome",[13,14,15,16,17],"Biological: Superficial skin swabs","Biological: Stool samples","Biological: Saliva samples","Biological: Blood samples","Other: Data-Collection",{"label":19,"type":10,"description":20,"interventionNames":21},"Control subjects","15 control subjects of the same age group and gender, treated at the service but with no dermatosis or inflammatory and\u002For autoimmune diseases.",[13,14,15,16,17],[23,28,31,35,39,43,45,49],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"BIOLOGICAL","Superficial skin swabs","Sampling areas: (18 swabs in total + 6 swabs for routine skin mapping)\n\n1. Lesion area outside skin folds (e.g., back or limb)\n2. Healthy area outside skin folds (e.g., back or limb)\n3. Perioral area of the face\n4. Scalp\n5. Inguinal fold\n6. Axillary fold",[9],{"type":24,"name":25,"description":29,"armGroupLabels":30,"otherNames":10},"Three superficial skin swabs: same locations as for Netherton patients",[19],{"type":24,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Stool samples","A stool sample collected for analysis of the fecal microbiome and mycobiome.",[19,9],{"type":24,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Saliva samples","A saliva sample collected for analysis of the saliva microbiome and mycobiome.",[19,9],{"type":24,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"Blood samples","For group A: cytokine profile from an additional blood sample taken during a blood draw for treatment For group B: cytokine profile if there is any residual blood sample from the treatment",[19],{"type":24,"name":40,"description":41,"armGroupLabels":44,"otherNames":10},[9],{"type":6,"name":46,"description":47,"armGroupLabels":48,"otherNames":10},"Data-Collection","Socio-demographic data and lifestyle habits of the patient and parents",[19,9],{"type":6,"name":46,"description":50,"armGroupLabels":51,"otherNames":10},"Clinical data, treatment data, and results of biological tests carried out as part of routine monitoring",[9],[53,59],{"name":54,"role":55,"phone":56,"phoneExt":57,"email":58},"Christine BODEMER, PhD","CONTACT","01 44 49 46 72","+33","christine.bodemer@aphp.fr",{"name":60,"role":55,"phone":61,"phoneExt":57,"email":62},"Victor BRUYERE, MSc","01 34 29 23 24","victor.bruyere@aphp.fr",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Hôpital Necker Enfants Malades","RECRUITING","Paris","Île-de-France Region","75015","France","FR",{"type":73,"coordinates":74},"Point",[75,76],2.3488,48.85341,{"lat":76,"lon":75},[79,80],{"name":54,"role":55,"phone":56,"phoneExt":57,"email":58},{"name":81,"role":55,"phone":82,"phoneExt":57,"email":83},"Nathalia BELLON, Dr","01 44 49 57 88","nathalia.bellon@aphp.fr",{"type":85,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[87],{"name":88,"class":6},"URC-CIC Paris Descartes Necker Cochin","100614476","study-of-skin-and-gut-microbiome-in-a-skin-condition-involving-skin-barrier-impairment-and-allergic-symptoms-netherton-syndrome-100614476",false,"NCT07280091","Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome","DERMABIOTE","Inclusion Criteria:\n\nGroup A:\n\n* Children aged 10 years and older and adults with confirmed Netherton syndrome diagnosed at age 10 years or older (clinical and histological and\u002For molecular)\n* Patients and legal guardians informed about the study and not opposed to participation in the study\n\nGroup B:\n\n* Children aged 10 years and older and adults with no skin barrier impairment, dermatosis, inflammatory disease, or autoimmune disease.\n* Subjects and legal guardians informed about the study and who do not object to participation in the study.\n\nExclusion Criteria:\n\n* Refusal by parents\u002Fguardians, children, adolescents, or adults.\n* General or local antibiotic therapy within the month preceding the consultation.","ALL","10 Years",{"count":99,"type":100},30,"ESTIMATED","OBSERVATIONAL","It is proposed to conduct an exploratory study to analyze the skin, intestinal, and salivary microbiome, as well as the skin mycobiome and virome, of patients (adolescents and young adults) with Netherton syndrome, a condition characterized by an impaired skin barrier that most likely promotes the development of allergic manifestations.\n\nThe study will be conducted on patients with Netherton syndrome and control subjects in order to investigate possible correlation factors between the three microbiomes and identify which ones.",[104],"Netherton Syndrome",[106,107],"Netherton syndrome","skin microbiome","2026-06-29",{"date":110,"type":111},"2026-06-30","ACTUAL",{"date":113,"type":111},"2026-05-26",{"date":115,"type":100},"2028-05",{"name":5,"class":6},1]